ARA-290: The Part of EPO That Repairs Without the Part That Thickens Blood

What Is ARA-290?

ARA-290 is an eleven-amino-acid peptide derived from a specific region of erythropoietin — the hormone best known for driving red blood cell production. The point of it is separation: EPO turns out to have a tissue-protective role quite distinct from its blood-forming one, and ARA-290 targets only the former.

Splitting one hormone in two, in plain language: imagine a tool that is both a hammer and a screwdriver welded together. Useful, until you only want to drive a screw and keep denting the wall. EPO is like that. One end raises red blood cell count — the reason it is infamous in endurance sport, and the reason it thickens blood dangerously if overused. The other end quietly protects and repairs tissue, working through an entirely different receptor. ARA-290 is the screwdriver cut free of the hammer: the repair signal without the blood-thickening one.

What the Research Examines

The tissue-protective activity runs through what researchers call the innate repair receptor — a different receptor complex from the one governing red cell production. That structural separation is what makes the split possible in the first place.

Clinical work has focused on small-fibre neuropathy, including trials in sarcoidosis-related neuropathy and in diabetes, examining neuropathic pain and small-fibre nerve measures. Results have been described as encouraging but the programme has not produced regulatory approval, and the compound remains investigational.

Frequently Asked Questions

Published References

1. Brines M, Patel NS, Villa P, et al. “Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.” Proceedings of the National Academy of Sciences of the United States of America, 2008. PubMed
2. Dahan A, Dunne A, Swartjes M, et al. “ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.” Molecular medicine (Cambridge, Mass.), 2013. PubMed
   The 2016 erratum corrects the corneal nerve fibre area calculation: reported areas require a factor of 2.26, with a further factor of 6.32 for the stated normalisation. Use the corrected source for these values. View notice
3. Brines M, Cerami A. “The receptor that tames the innate immune response.” Molecular medicine (Cambridge, Mass.), 2012. PubMed
4. Culver DA, Dahan A, Bajorunas D, et al. “Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.” Investigative ophthalmology & visual science, 2017. PubMed